QNCX — Quince Therapeutics Cashflow Statement
0.000.00%
Last trade - 00:00- $32.41m
- -$21.89m
- 25
- 49
- 26
- 25
Annual cashflow statement for Quince Therapeutics, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Net Income/Starting Line | -37 | -76.8 | -89.9 | -51.7 | -31.4 |
| Depreciation | |||||
| Deferred Taxes | |||||
| Non-Cash Items | 1.61 | 15.5 | 30.9 | 17.4 | 11 |
| Unusual Items | |||||
| Other Non-Cash Items | |||||
| Changes in Working Capital | 1.9 | 10.2 | -4.26 | -9.73 | 2.01 |
| Change in Prepaid Expenses | |||||
| Change in Other Assets | |||||
| Change in Accounts Payable | |||||
| Change in Accrued Expenses | |||||
| Cash from Operating Activities | -33.3 | -50.8 | -62.9 | -44 | -18.3 |
| Capital Expenditures | -0.055 | -0.052 | -0.18 | -0.133 | -0.16 |
| Purchase of Fixed Assets | |||||
| Other Investing Cash Flow Items | -17.7 | -52.4 | 59.1 | 18.1 | -5.6 |
| Acquisition of Business | |||||
| Sale/Maturity of Investment | |||||
| Purchase of Investments | |||||
| Other Investing Cash Flow | |||||
| Cash from Investing Activities | -17.7 | -52.4 | 59 | 18 | -5.76 |
| Net Issuance / Retirement of Stock | |||||
| Net Issuance / Retirement of Debt | |||||
| Cash from Financing Activities | 77.4 | 119 | 6.81 | 0.707 | 0.143 |
| Foreign Exchange Effects | |||||
| Beginning Cash Balance | |||||
| Ending Cash Balance | |||||
| Net Change in Cash | 26.3 | 15.6 | 2.88 | -25.1 | -23.8 |